Corporate Profile
To become a world leader in the development of targeted antiviral therapies for chronic hepatitis B (CHB) and COVID-19 and to leverage our expertise in liver diseases to create optimized therapeutics for NASH.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Events
Nov 22, 2021 at 10:00 AM EST
Nov 18, 2021 at 8:00 AM GMT